Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MASH patients share their hopes and challenges in new interview study

NCT ID NCT07188220

Knowledge-focused Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study interviews 25 people with MASH (a fatty liver disease linked to metabolism) to learn about their expectations, attitudes, and unmet needs before and after joining a special heart-liver program. Participants will have two private interviews. The goal is to improve care by hearing directly from patients, not to test any new drug or treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of individuals diagnosed with MASH who are referred to the multidisciplinary MASH-Cardiovascular Programme at Hospital de la Santa Creu i Sant Pau in Barcelona.

Ages

18 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who voluntarily agree to participate in the MASH-Cardiovascular Programme. * Patients followed in the outpatient hepatology/gastroenterology clinic at Hospital de Sant Pau with a diagnosis of MASH and fibrosis stage F2-F4. * Patients aged between 18 and 75 years. * Patients with a BMI ≥ 27 kg/m². * Patients who consent to participate in the study-specific interviews. Exclusion Criteria: * Patients who do not agree to participate in the study-specific interviews. * Patients meeting exclusion criteria of the MASH-Cardiovascular Programme: * Patients with decompensated liver cirrhosis. * Patients who are vegetarians or have dietary habits/preferences that prevent adherence to standard-of-care nutritional guidelines. * Patients with moderate-to-severe alcohol consumption (\>20 g/day for women and \>40 g/day for men). * Patients with an eGFR \< 30 mL/min. * Patients with malnutrition. * Patients with type 1 diabetes or other forms of diabetes. * Patients who are candidates for bariatric surgery. * Patients with active malignancy. * Patients with advanced or unstable heart failure. * Patients with eating disorders or severe psychiatric illness. * Patients currently enrolled in another clinical trial. * Pregnant women or women planning to become pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic dysfunction associated steatohepatitis (MASH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction associated steatohepatitis (MASH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IR Sant Pau

    RECRUITING

    Barcelona, 08041, Spain

  • IR Sant Pau

    RECRUITING

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.